Pegylated liposomal-encapsulated doxorubicin in cutaneous composite lymphoma: A case report.

Medicine (Baltimore)

Department of Dermatology and Allergology, Insitute of Pathology "Georg Schmorl", Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany.

Published: October 2016

AI Article Synopsis

  • Cutaneous composite lymphomas, including aggressive PTCL-NOS and indolent FCBCL, have varied treatment approaches, with limited reports on the use of pegylated liposomal doxorubicin (PLE-DOXO).
  • A 73-year-old male patient with this composite lymphoma experienced initial surgical removal of lesions, followed by successful treatment with PLE-DOXO, leading to a complete remission of skin lesions.
  • After subsequent relapses and various treatments, the patient's overall survival lasted 28 months, highlighting the potential of PLE-DOXO as a viable systemic treatment option, though the benefits of further chemotherapy remain uncertain.

Article Abstract

Background: Cutaneous composite lymphomas are very rare. Their treatment depends upon the different contributing lymphoma entities. Peripheral T-cell lymphoma, not otherwise specified, (PTCL-NOS) represents an aggressive lymphoma subtype. Follicular cutaneous B-cell lymphoma (FCBCL) runs an indolent course. Treatment with pegylated liposomal encapsulated doxorubicin (PLE-DOXO) has yet not been reported in this entity.

Case Presentation: A 73-year-old male patient presented with 3 rapidly growing, painful nodules on his left leg. He was diagnosed as composite cutaneous lymphoma consisting of PTCL-NOS and FCBCL. All lesions had been surgically removed. Staging was unremarkable. After 4 months a relapse occurred with involvement of inguinal lymph nodes and systemic treatment with PEL-DOXO 20 mg/ m every 3 weeks was initiated. After 6 cycles PLE-DOXO, which were well tolerated without grade 3 or 4 toxicities, a mixed response was obtained with complete remission of cutaneous lesions.Lymph nodes were treated by radiotherapy. A second relapse occurred after 8 months and various polychemotherapy regimens were applied without remission. The overall survival was 28 months.

Conclusion: PEL-DOXO is a possible initial systemic treatment in case of PCTL-NOS. Whether polychemotherapy offers an advantage for survival remains questionable but further investigations are needed.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089085PMC
http://dx.doi.org/10.1097/MD.0000000000004796DOI Listing

Publication Analysis

Top Keywords

cutaneous composite
8
relapse occurred
8
systemic treatment
8
lymphoma
6
cutaneous
5
pegylated liposomal-encapsulated
4
liposomal-encapsulated doxorubicin
4
doxorubicin cutaneous
4
composite lymphoma
4
lymphoma case
4

Similar Publications

The capacity for tissue repair during wound healing declines with age. A chronic low but systemic inflammatory status, often called "inflammaging", is considered a key factor that contributes to impaired tissue regeneration. This phenomenon has been substantiated by an increased number of immune cells in wound-tissue of old mice.

View Article and Find Full Text PDF

Clozapine is a potent serotonin receptor antagonist and commonly used for the treatment of Schizophrenia. The study aimed to develop and optimize the transdermal matrix patch of clozapine. A 3-level, 3-factor Central Composite Design was applied to examine and validate the impact of various formulation variables, Eudragit, PEG, and oleic acid on in vitro drug release, flux, and tensile strength (TS).

View Article and Find Full Text PDF

Optimization and Standardization of Stable De-Epidermized Dermis (DED) Models for Functional Evaluation of Cutaneous Cell Therapies.

Bioengineering (Basel)

December 2024

Plastic, Reconstructive and Hand Surgery Service, Lausanne University Hospital, University of Lausanne, CH-1011 Lausanne, Switzerland.

The human skin is a remarkable organ capable of extensive regeneration, especially after severe injuries such as burns and related wounds. The de-epidermized dermis (DED) model has become a valuable in vitro tool for skin regeneration studies, particularly for testing the mechanism of action and the efficacy of clinical cutaneous cell therapies. To further improve the quality and robustness of these applications, our study focused on optimizing and standardizing DED tissue preparation and storage, enhancing its effectiveness for clinical testing.

View Article and Find Full Text PDF

Multi-Layered Microneedles Loaded with Microspheres.

AAPS PharmSciTech

January 2025

School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, 311 Ferst Drive, Atlanta, Georgia, 30332-0100, U.S.A..

Delivery of therapies into skin is attractive for medical indications including vaccination and treatment of dermatoses but is highly constrained by the stratum corneum barrier. Microneedle (MN) patches have emerged as a promising technology to enable non-invasive, intuitive, and low-cost skin delivery. When combined with biodegradable polymer formulations, MN patches can further enable controlled-release drug delivery without injection.

View Article and Find Full Text PDF

Previous research has demonstrated that postural stability may be improved by increasing stimulation to the somatosensory system. Wearing lower limb compression garments or textured in-soles have been found to be effective short-term methods for improving postural stability, hypothesized to be due to enhanced tactile feedback. The aim of this study was to assess whether a combined compression-tactile sock increases postural stability in healthy adults, compared to barefoot.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!